Overview

Infusion of Apomorphine: Long-term Safety Study

Status:
Active, not recruiting

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

This is a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinson's Disease (PD) whose motor fluctuations remain unsatisfactory with levodopa (or levodopa/carbidopa) and at least one other class of drugs or mode of therapy for PD.

Phase:

Phase 3

Details

Lead Sponsor:

US WorldMeds LLC

Treatments:

Apomorphine